Problem Solved
Traditional cancer treatments often struggle with delivering potent drugs directly to tumor cells without affecting healthy cells. This lack of precision can lead to severe side effects and reduced treatment efficacy.
Core Features
This invention introduces modified peptide ligands that can deliver highly potent drugs directly to tumor cells. The core innovation lies in the use of specific conjugation chemistries to LHRH analogs, which are modified to enhance stability and effectiveness. These ligands can carry one or multiple drug payloads, ensuring targeted delivery.
Inventive Step
The novel aspect of this invention is the introduction of specific amino acid substitutions and four unique conjugation chemistries—triazole, thioether, oxime, and amide bonds—that enhance the stability and potency of the peptide drug conjugates (PDCs). These modifications allow the drugs to remain stable in the bloodstream and release their payloads specifically within cancer cells, minimizing damage to healthy cells.
Benefits
The invention offers a more stable and potent drug delivery system, reducing side effects and increasing the efficacy of cancer treatments. It provides a safer alternative to existing PDCs and small molecule drug conjugates, potentially leading to better patient outcomes.
Broader Impact
This innovation could significantly improve cancer treatment protocols, making therapies more effective and less harmful. It has the potential to transform the pharmaceutical industry by setting a new standard for targeted drug delivery, ultimately contributing to better healthcare outcomes and reduced treatment costs.